Hprt mutant frequency and molecular analysis of Hprt mutations in Fischer 344 rats treated with thiotepa

Carcinogenesis

Volumn 20, Issue 2, 1999, Pages 269-277

  Chen, Tao ^a,b   Aidoo, Anane ^a   Mittelstaedt, Roberta A ^a   Casciano, Daniel A ^a   Heflich, Robert H ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOGEN; COMPLEMENTARY DNA; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MESSENGER RNA; THIOTEPA;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DNA SEQUENCE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHUMAN; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

ADENINE; AMINO ACID SUBSTITUTION; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOGENS; CYTOSINE; GUANOSINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MALE; MUTAGENICITY TESTS; POINT MUTATION; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; THIOTEPA; THYMIDINE; TIME FACTORS;

EID: 0032937783     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.2.269     Document Type: Article

References (74)

1. Wright, J.C., Colomb, F.M. and Gumport, S.L. (1958) Summary of results with triethylene thiophosphoramide. Ann. NY Acad. Sci., 68, 937-966.
2. Hollister, D. Jr and Coleman, M. (1980) Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma. J. Am. Med. Assoc., 18, 2065-2067.
3. Hagen, B., Walseth, F., Walstad, R.A., Iversen, T. and Nilsen, O.G. (1987) Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma. Cancer Chemother. Pharmacol., 19, 143-148.
4. Reynolds, J.E.F. (1989) Martindale. The Extra Pharmacopoeia. The Pharmaceutical Press, London, UK, pp. 652-653.
5. IARC (1990) Thiotepa. In Pharmaceutical Drugs, IARC Scientific Publications no. 50, IARC, Lyon, pp. 123-141.
6. Bacigalupo, A., Van, L.M., Valbonesi, M. et al. (1990) Thiotepa and cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. Blood, 88, 353-357.
7. Bouffet, E., Mottolese, C., Jouvet, A., Philip, I., Frappaz, D., Carrie, C. and Brunatmentigny, M. (1997) Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high grade gliomas. Eur. J. Cancer, 33, 91-95.
8. Schmahl, D. and Osswald, H. (1970) Experimental studies on carcinogenic effects of anticancer chemotherapeutics and immunosuppressives. Arzneimittelforschung, 20, 1461-1467.
9. Stoner, G.D., Shimkin, M.B., Kniazeff, A.J., Weisburger, J.H., Weisburger, E.K. and Gori, G.B. (1973) Test for carcinogenicity of food additives and chemotherapeutic agents by the pulmonary tumor response in strain A mice. Cancer Res., 33, 3069-3085.
10. Schmahl, D. (1975) Experimental investigations with anti-cancer drugs for carcinogenicity with special reference to immunedepression. In Grundmann, E. and Gross, R. (eds) The Ambivalence of Cytostatic Therapy. Springer, Berlin, Germany, pp. 18-28.
11. National Cancer Institute (1978) Bioassay of Thiotepa for Possible Carcinogenicity, Technical Report Series no. 58, DHEW Publication no. (NIH) 78-1308. US Government Printing Office, Washington, DC.
12. Nakanuma, Y., Saiki, S., Hisazumi, H. and Matsubara, F. (1976) An autopsy case of atypical leukemia occurred during thiotepa administration. Jpn. J. Clin. Hematol., 20, 75-81.
13. Sheibani, K., Bukowski, R.M., Tubbs, R.R., Savage, R.A., Sebek, B.A. and Hoffman, G.C. (1980) Acute nonlymphocytic leukemia in patients receiving chemotherapy for nonmalignant diseases. Hum. Pathol., 11, 175-179.
14. Easton, D.J. and Poon, M.A. (1983) Acute nonlymphocytic leukaemia following bladder installations with thiotepa. Can. Med. Assoc. J., 129, 578-579.
15. Silberberg, J.M. and Zarrabi, M.H. (1987) Acute nonlymphocytic leukemia after thiotepa instillation into the bladder: report of 2 cases and review of the literature. J. Urol., 138, 402-403.
16. Kaldor, J.M., Day, N.E., Petersson, F. et al. (1990) Leukemia following chemotherapy for ovarian cancer. New Engl. J. Med., 322, 1-6.
17. Benedict, W.F., Banerjee, A., Gardner, A. and Jones, P.A. (1977) Induction of morphological transformation in mouse C3H10T1/2 clone 8 cells and chromosomal damage in hamster A(T1)C1-3 cells by cancer chemotherapeutic agents. Cancer Res., 37, 2202-2208.
18. Yakovenko, K.N. and Kagramanyan, S.A. (1982) Combined action of thiophosphamide and dipin on chromosomes of human lymphocytes. Cytol. Genet., 11, 53-56.
19. Shcheglova, E.G. and Chebotarev, A.N. (1983) Comparison of level of sister chromatid exchanges and chromosomal aberrations induced by chemical mutagens in vitro. Bull. Exp. Biol. Med., 96, 1604-1606.
20. Maier, P. and Schmid, W. (1976) Ten model mutagens evaluated by the micronucleus test. Mutat. Res., 40, 325-338.
21. Setnikar, I., Magistretti, M.J. and Veronese, M. (1976) Mutagenicity studies on nifurpipone and nitrofurantoin. Proc. Eur. Soc. Toxicol. 17, 405-412.
22. Semenov, K.K. and Malashenko, A.M. (1981) Appearance of dominant lethal mutations during early embryogenesis of the mouse. Sov. Genet., 17, 309-313.
23. Bochkov, N.P., Stukalov, S.V. and Chebotarev, A.N. (1982) Comparison of the frequency of chromosomal aberrations induced by thiophosphamide in rabbit lymphocytes in vitro and in vivo. Bull. Exp. Biol. Med., 94, 1118-1121.
24. Kuzin, S.M., Stukalov, S.V. and Popandopulo, P.G. (1987) Quantitative comparison of the cytogenetic effect of thiophosphamide on monkey lymphocytes in vivo and in vitro. Bull. Exp. Biol. Med., 103, 394-396.
25. Malashenko, A.M. and Beskova, T.B. (1988) Induction of chromosome defects by thiophosphamide in spermatogonia of mice of inbred lines 101HY, PTS/Y, and CBA/LacY. Sov. Genet., 24, 320-325.
26. Selezneva, T.G. and Korman, N.P. (1973) Analysis of chromosomes of somatic cells in patients treated with antitumor drugs. Sov. Genet., 9, 1575-1579.
27. Benedict, W.F., Baker, M.S., Haroun, L., Choi, E. and Ames, B.N. (1977) Mutagenicity of cancer chemotherapeutic agents in the Salmonella/ microsome test. Cancer Res., 37, 2209-2213.
28. Bignami, M., Carere, A., Conti, G., Conti, L., Crebelli, R. and Fabrizi, M. (1982) Evaluation of 2 different genetic markers for the detection of frameshift and missense mutagens in A.nidulans. Mutat. Res., 97, 293-302.
29. Paschin, Y.V. and Kozachenko, V.I. (1982) The modifying effect of hexavalent chromate on the mutagenic activity of thiotepa. Mutat. Res., 103, 367-370.
30. Farber, S., Appleton, R., Downing, V., Heald, F. King, J. and Toch, R. (1953) Clinical studies on the carcinolytic action of triethylenephosphoramide. Cancer (Philad.), 6, 135-141.
31. Herzig, G.P. (1987) High-Dose Thiotepa and Autologous Marrow Transplantation; Advances in Cancer Chemotherapy. John Wiley & Sons, New York, NY.
32. Wolff, S.N., Herzing, R.H., Fay, J.W. et al. (1990) High dose N,N′,N″-triethylene-thiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin. Oncol., 17, 2-6.
33. Compton, P.J., Hooper, K. and Smith, M.T. (1991) Human somatic mutation assays as biomarkers of carcinogenesis. Environ. Health Perspect., 94, 135-141.
34. Albertini, R.J., Nicklas, J.A., Fuscoe, J.C., Skopek, T.R., Branda, R.F. and O'Neill, J.P. (1993) In vivo mutations in human blood cells: biomarkers for molecular epidemiology. Environ. Health Perspecl., 99, 135-141.
35. Husgafvel, P.K., Ridanpaa, M., Anttila, S. and Vainio, H. (1995) p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures. J. Occup. Environ. Med., 37, 69-76.
36. Nelson, E. (1996) Laboratory probing of oncogenes from human liquid and solid specimens as markers of exposure to toxicants. Crit. Rev. Toxicol., 26, 483-549.
37. Shen, H.M. and Ong, C.N. (1996) Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat. Res., 366, 23-44.
38. Aidoo, A., Lyn-Cook, L.E., Mittelstaedt, R.A., Heflich, R.H. and Casciano, D.A. (1991) Induction of 6-thioguanine-resistant lymphocytes in Fischer 344 rats following in vivo exposure to N-ethyl-N-nitrosourea and cyclophosphamide. Environ. Mol. Mutagen., 17, 141-151.
39. Aidoo, A., Lyn-Cook, L.E., Heflich, R.H., George, E.O. and Casciano, D.A. (1993) The effect of time after treatment, treatment schedule and animal age on the frequency of 6-thioguanine-resistant T-lymphocytes induced in Fischer 344 rats by N-ethyl-N-nitrosourea. Mutat. Res., 298, 169-178.
40. Aidoo, A., Morris, S.M. and Casciano, D.A. (1997) Development and utilization of the rat lymphocyte hprt mutation assay. Mutat. Res., 387, 69-88.
41. Mittelstaedt, R.A. and Heflich, R.H. (1994) Analysis of in vivo mutation in exon 8 of the rat hprt gene. Mutat. Res., 311, 139-148.
42. Mittelstaedt, R.A., Smith, B.A. and Heflich, R.H. (1995) Analysis of in vivo mutation induced by N-ethyl-N-nitrosourea in the hprt gene of rat lymphocytes. Environ. Mol. Mutagen., 26, 261-269.
43. Heflich, R.H., Mittelstaedt, R.A., Manjanatha, M.G., Lyn-Cook, L.E. and Aidoo, A. (1996) DNA sequence analysis of hprt mutations in lymphocytes from Sprague-Dawley rats treated with 7,12-dimethylbenz[a]anthracene. Environ. Mol. Mutagen., 28, 5-12.
44. Smith, B.A., Fullerton, N.F., Heflich, R.H. and Beland, F.A. (1995) DNA adduct formation and T-lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene. Cancer Res., 55, 2316-2324.
45. Chen, T., Aidoo, A., Casciano, D.A. and Heflich, R.H. (1998) Expansion of rat 6-thioguanine-resistant T-lymphocyte clones by stimulation with ionomycin and a phorbol ester. Environ. Mol. Mutagen., 31, 97-102.
46. Chen, T., Mittelstaedt, R.A. and Heflich, R.H. (1998) DNA sequence flanking the protein coding regions of the rat Hprt gene. Mutat Res., 382, 79-80.
47. Jansen, J.C., Vrieling, H., van Zeeland, A. and Mohn, G.R. (1992) The gene encoding hypoxanthine-guanine phosphoribosyltransferase as target for mutational analysis: PCR cloning and sequencing of the cDNA from the rat. Mutat. Res., 266, 105-116.
48. Wright, S.P. (1992) Adjusted p-values for simultaneous inference. Biometrics, 48, 1005-1013.
49. Cariello, N.F. and Skopek, T.R. (1993) Analysis of mutations occurring at the human hprt locus. J. Mol. Biol., 231, 41-57.
50. Hennings, H., Glick, A.B., Greenhalgh, D.A., Morgan, D.L., Strickland, J.E., Tennenbaum, T. and Yuspa, S.H. (1993) Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. Proc. Soc. Exp. Biol. Med., 202, 1-8.
51. Sanderson, B.J. and Shield, A.J. (1996) Mutagenic damage to mammalian cells by therapeutic alkylaling agents. Mutat. Res., 355, 41-57.
52. Teicher, B.A., Holden, S.A., Cucchi, C.A., Cathcart, K.N., Korbut, T.T., Flatow, J.L. and Frei, E. (1988) Combination of N,N′,N″-triethylene-thiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res., 48, 94-100.
53. Cohen, N.A., Egorin, M.J., Snyder, S.W., Ashar, B., Wietharn, B.E., Pan, S.S., Ross, D.D. and Hilton, J. (1991) Interaction of N,N′,N″-triethylene-thiophosphoramide and N,N′,N″-triethylenephosphoramide with cellular DNA. Cancer Res., 51, 4360-4366.
54. Musser, S.M., Pan, S.S., Egorin, M.J., Kyle, D.J. and Callery, P.S. (1992) Alkylation of DNA with aziridine produced during the hydrolysis of N,N′,N″-triethylenethiophosphoramide. Chem. Res. Toxicol., 5, 95-99.
55. Andrievsky, G.V., Sukhodub, L.F., Pyatigorskaya, T.L., Boryak, O.A., Limanskaya, O. and Shelkovsky, V.S. (1991) Direct observation of the alkylation products of deoxyguanosine and DNA by fast atom bombardment mass spectrometry. Biol. Mass Spectrom., 20, 665-668.
56. Musser, S.M., Pan, S.S. and Callery, P.S. (1989) Liquid chromatography-thermospray mass spectrometry of DNA adducts formed with mitomycin C, porfiromycin and thiotepa. J. Chromatogr., 474, 197-207.
57. Muller, N. and Eisenbrand, G. (1985) The influence of N7 substituents on the stability of N7-alkylated guanosines. Chem. Biol. Interact., 53, 173-181.
58. Gill, R.D., Cussac, C., Souhami, R.L. and Laval, F. (1996) Increased resistance to N,N′,N″-triethylenethiophosphoramide (thiotepa) in cells expressing the Escherichia coli formamidopyrimidine-DNA glycosylase. Cancer Res., 56, 3721-3724.
59. Natarajan, A.T. Simons, J.W., Vogel, E.W. and van Zeeland, A.A. (1984) Relationship between cell killing, chromosomal aberrations, sister-chromatid exchanges and point mutations induced by monofunctional alkylating agents in Chinese hamster cells. A correlation with different ethylation products in DNA. Mutat. Res., 128, 31-40.
60. Kunkel, T.A. (1984) Mutational specificity of depurination. Proc. Natl Acad. Sci. USA, 81, 1494-1498.
61. Sagher, D. and Strauss, B. (1983) Insertion of nucleotides opposite apurinic/ apyrimidinic sites in deoxyribonucleic acid during in vitro synthesis: uniqueness of adenine nucleotides. Biochemistry, 22, 4518-4526.
62. Vogel, E.W. and Nivard, M.J.M. (1984) The subtlety of alkylating agents in reactions with biological macromolecules. Mutat. Res., 305, 13-32.
63. Paustenbach, D.J., Finley, B.L. and Kacew, A.S. (1996) Biological relevance and consequences of chemical-or metal-induced DNA cross-linking. Proc. Soc. Exp. Biol. Med., 211, 211-217.
64. Chen, W.F., Ewing, T., Scollay, R. and Shortman, K. (1988) Growth of single T cells and single thymocytes in a high cloning efficiency filler-cell free microculture system. Thymus, 12, 51-68.
65. Jones, J.M., Burkhart-Schultz, K. and Crippen, T.L. (1987) Cloned mouse lymphocytes permit analysis of somatic mutations that occur in vivo. Somat. Cell Mol. Genet., 13, 325-333.
66. Skopek, T.R., Walker, V.E., Cochrane, J.E., Craft, T.R. and Cariello, N.F. (1992) Mutational spectrum at the Hprt locus in splenic T cells of B6C3F1 mice exposed to N-ethyl-N-nitrosourea. Proc. Natl Acad. Sci. USA, 89, 7866-7870.
67. 6-alkylguanine in hprt mutagenesis in T-lymphocytes of rats exposed in vivo to ethylmethanesulfonate, N-(2-hydroxyethyl)-N-nitrosourea, or N-ethyl-N-nitrosourea. Cancer Res., 55, 1875-1882.
68. Gibbs, R.A., Nguyen, P.N., Edwards, A., Civitello, A.B. and Caskey, C.T. (1990) Multiplex DNA deletion detection and exon sequencing of the hypoxanthine phosphoribosyltransferase gene in Lesch-Nyhan families. Genomics, 7, 235-244.
69. Simpson, D., Crosby, R.M. and Skopek, T.R. (1988) A method for specific cloning and sequencing of human hprt cDNA for mutation analysis Biochem. Biophys. Res. Commun., 151, 487-492.
70. Rossiter, B.J., Fuscoe, J.C., Muzny, D.M., Fox, M. and Caskey, C.T. (1991) The Chinese hamster HPRT gene: restriction map, sequence analysis, and multiplex PCR deletion screen. Genomics, 9, 247-256.
71. Fuscoe, J.C. Fenwick, R.J., Ledbetter, D.H. and Caskey, C.T. (1983) Deletion and amplification of the HGPRT locus in Chinese hamster cells. Mol. Cell. Biol., 3, 1086-1096.
72. Heflich, R.H. and Neft, R.E. (1994) Genetic toxicity of 2-acetyl-aminofluorene, 2-aminofluorene and some of their metabolites and model metabolites. Mutat. Res., 318, 73-174.
73. Chen, T., Mittelstaedt, R.A. and Heflich, R.H. (1997) Multiplex PCR for the analysis of deletion mutation in the rat lymphocyte hprt assay. Environ. Mol. Mutagen., 29, 9.
74. Valentine, C.R. and Heflich, R.H. (1997) The association of nonsense mutation with exon-skipping in hprt mRNA of Chinese hamster ovary cells results from an artifact of RT-PCR. RNA. 3, 660-676.